Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition
ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Sex
Male or Female
Age
18+ years
Healthy participants
No

Eligibility criteria

Study overview

This study aims to assess the prognostic utility of various markers of disease progression among patients diagnosed with ATTR-CM treated with tafamidis utilizing Truveta database in the US. We will evaluate the impact of markers of disease progression (such as eGFR, ODI, NT-proBNP, NYHA and KCCQ) at Month 12 after initiation of tafamidis on clinical outcomes (including all-cause mortality, CV-related mortality, first CV hospitalization) among ATTR-CM patients treated with tafamidis in the US.

View locations for this study

Find the closest location, your results will be shown below
Find the closest location
    Miles
    0500

    Nearest Locations found

    0 site found
    • Recruitment Status
    • Site details
    • Study Contact
    • Clinical Trials ID

    Study Locations

    View locations for this studyFind the closest location, your results will be shown belowFind the closest location